Savant Capital LLC Purchases 653 Shares of AbbVie Inc. (NYSE:ABBV)

Savant Capital LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 154,482 shares of the company’s stock after purchasing an additional 653 shares during the quarter. Savant Capital LLC’s holdings in AbbVie were worth $27,451,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Wagner Wealth Management LLC boosted its holdings in AbbVie by 9.2% in the 4th quarter. Wagner Wealth Management LLC now owns 4,030 shares of the company’s stock worth $716,000 after buying an additional 338 shares during the period. Angeles Wealth Management LLC raised its holdings in AbbVie by 9.2% during the 4th quarter. Angeles Wealth Management LLC now owns 14,268 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,201 shares during the period. Liberty Capital Management Inc. lifted its position in shares of AbbVie by 0.3% during the fourth quarter. Liberty Capital Management Inc. now owns 39,251 shares of the company’s stock worth $6,975,000 after acquiring an additional 103 shares in the last quarter. OMC Financial Services LTD grew its position in shares of AbbVie by 4.6% in the fourth quarter. OMC Financial Services LTD now owns 52,025 shares of the company’s stock valued at $9,245,000 after purchasing an additional 2,276 shares in the last quarter. Finally, Legacy Financial Strategies LLC grew its position in shares of AbbVie by 0.4% in the fourth quarter. Legacy Financial Strategies LLC now owns 18,631 shares of the company’s stock valued at $3,343,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.25% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $190.67 on Monday. The stock has a market capitalization of $336.94 billion, a price-to-earnings ratio of 79.45, a PEG ratio of 1.53 and a beta of 0.58. The firm’s 50-day moving average price is $177.54 and its two-hundred day moving average price is $185.69. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period in the prior year, the firm earned $2.79 earnings per share. As a group, equities analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on ABBV. Daiwa Capital Markets downgraded AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research note on Thursday, December 5th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. Wolfe Research began coverage on AbbVie in a research note on Friday, November 15th. They issued an “outperform” rating and a $205.00 target price on the stock. JPMorgan Chase & Co. cut their price objective on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. Finally, Argus raised AbbVie from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.35.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.